Mar 17, 2025 · Cereno Scientific is well-positioned for strong growth in an attractive cardiovascular and pulmonary rare disease market with an innovative pipeline of clinical and …

Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare …

Cereno’s pipeline comprises the Phase II drug candidate CS1, the Phase I drug candidate CS014 and the preclinical asset CS585.

Based in Sweden, Cereno Scientific is focused on the development of innovative, effective and safe treatments for people with rare cardiovascular and pulmonary diseases. Lead asset CS1, …

Oct 2, 2024 · Cereno Scientific‘s investigational therapy CS1 was well tolerated and showed signs of clinical benefit in people with pulmonary arterial hypertension (PAH), according to top-line …

Jun 18, 2024 · Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the …

Mar 12, 2025 · Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary …

Find the latest Cereno Scientific AB (publ) (CRNO-B.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

Feb 2, 2024 · The U.S. Food and Drug Administration (FDA) has approved Cereno Scientific’s investigational drug CS1 in an extension of the ongoing Phase 2 clinical trial testing it in …

Drug candidate CS1 is an innovative formulation of valproic acid (VPA) and is an HDAC inhibitor that works through epigenetic modulation, being developed as a treatment for the rare disease …